Stock 000790 CHENGDU HUASUN TECHNOLOGY GROUP INC. , LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chengdu huasun technology group Inc. , LTD.

Equities

000790

CNE0000001H5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
4.24 CNY +10.13% Intraday chart for Chengdu huasun technology group Inc. , LTD. +14.29% -16.21%
May. 03 Huasun Technology to Cancel 3.8 Million Repurchased Shares MT
Apr. 29 Chengdu huasun technology group Inc. , LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,275 2,792 2,712 3,980 2,860 3,178
Enterprise Value (EV) 1 1,929 2,388 2,285 3,723 2,906 3,383
P/E ratio 73.1 x 45.3 x 73.3 x 57.8 x 65 x 127 x
Yield 0.74% 0.22% 0.23% 0.16% 0.22% -
Capitalization / Revenue 3.59 x 3.75 x 3.57 x 4.21 x 3.28 x 3.17 x
EV / Revenue 3.05 x 3.2 x 3.01 x 3.94 x 3.33 x 3.37 x
EV / EBITDA 34.6 x 27.8 x 33.1 x 38.3 x 38.1 x 37.6 x
EV / FCF 28.8 x 41.5 x 79.7 x -23.1 x 70.1 x -30.9 x
FCF Yield 3.47% 2.41% 1.25% -4.32% 1.43% -3.24%
Price to Book 2.72 x 3.17 x 2.97 x 4.08 x 2.85 x 4.32 x
Nbr of stocks (in thousands) 616,361 616,361 616,361 625,774 628,574 628,143
Reference price 2 3.691 4.530 4.400 6.360 4.550 5.060
Announcement Date 3/12/19 4/16/20 4/8/21 4/29/22 4/27/23 4/29/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 633.4 745.3 759.3 945.3 873.1 1,003
EBITDA 1 55.7 85.92 68.95 97.12 76.21 89.85
EBIT 1 33.98 69.94 53.74 81.83 45.32 57.24
Operating Margin 5.36% 9.38% 7.08% 8.66% 5.19% 5.71%
Earnings before Tax (EBT) 1 43.31 75.75 44.43 83 41.7 29.27
Net income 1 31.17 61.63 37.5 70.32 41.22 27.66
Net margin 4.92% 8.27% 4.94% 7.44% 4.72% 2.76%
EPS 2 0.0505 0.1000 0.0600 0.1100 0.0700 0.0400
Free Cash Flow 1 66.88 57.53 28.66 -160.9 41.45 -109.5
FCF margin 10.56% 7.72% 3.77% -17.02% 4.75% -10.91%
FCF Conversion (EBITDA) 120.08% 66.96% 41.56% - 54.39% -
FCF Conversion (Net income) 214.56% 93.35% 76.41% - 100.57% -
Dividend per Share 2 0.0273 0.0100 0.0100 0.0100 0.0100 -
Announcement Date 3/12/19 4/16/20 4/8/21 4/29/22 4/27/23 4/29/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 46.1 204
Net Cash position 1 346 404 427 257 - -
Leverage (Debt/EBITDA) - - - - 0.6049 x 2.272 x
Free Cash Flow 1 66.9 57.5 28.7 -161 41.5 -109
ROE (net income / shareholders' equity) 3.72% 7.18% 4.17% 7.36% 3.4% 2.84%
ROA (Net income/ Total Assets) 1.76% 3.93% 2.95% 4.18% 1.87% 1.88%
Assets 1 1,769 1,567 1,272 1,682 2,207 1,473
Book Value Per Share 2 1.360 1.430 1.480 1.560 1.600 1.170
Cash Flow per Share 2 0.5600 0.6600 0.6600 0.4900 0.2300 0.2400
Capex 1 11.2 1.49 2.52 108 165 189
Capex / Sales 1.76% 0.2% 0.33% 11.37% 18.94% 18.87%
Announcement Date 3/12/19 4/16/20 4/8/21 4/29/22 4/27/23 4/29/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CHENGDU HUASUN TECHNOLOGY GROUP INC. , LTD. Stock Chengdu huasun technology group Inc. , LTD.
-16.21% 368M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000790 Stock
  4. Financials Chengdu huasun technology group Inc. , LTD.